Reaktionsgleichung
[N:1]1([C:7]2[N:8]=[C:9]3[NH:17][C@H:16]([C:18]([F:21])([F:20])[F:19])[CH2:15][CH2:14][N:10]3[C:11](=[O:13])[CH:12]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.C(=O)([O-])[O-].[Cs+].[Cs+].Br[CH2:29][C:30]1[CH:35]=[CH:34][C:33]([F:36])=[C:32]([F:37])[C:31]=1[F:38]>CN(C)C=O>[N:1]1([C:7]2[N:8]=[C:9]3[N:17]([CH2:29][C:30]4[CH:35]=[CH:34][C:33]([F:36])=[C:32]([F:37])[C:31]=4[F:38])[C@H:16]([C:18]([F:20])([F:21])[F:19])[CH2:15][CH2:14][N:10]3[C:11](=[O:13])[CH:12]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1Komponenten
5
Edukt 3
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
The product is prepared according to the procedure described in Example 22, using 100 mg of (8S)-2-morpholin-4-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one (Example 1e), 214 mg of caesium carbonate and 82 mg of 1-(bromomethyl)-2,3,4-trifluorobenzene in 2 ml of dimethylformamide. After purification by preparative HPLC/MS (Method C), 76 mg of (8S)-2-(morpholin-4-yl)-9-(2,3,4-trifluorobenzyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one are obtained in the form of an oil, the characteristics of which are the following:
Aufarbeitung
- customThe product is prepared
- customAfter purification by preparative HPLC/MS (Method C), 76 mg of (8S)-2-(morpholin-4-yl)-9-(2,3,4-trifluorobenzyl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one
- customare obtained in the form of an oil
Quellen und Nachweise
- ORD-Eintrag
- ord-fb05c310a9b7498d8eb7f9f9c397a575
- Quelldatensatz
- uspto-grants-2014_09
- Patentnummer
- US08846670B2
Verknüpfte Notizen
Wird geladen…